产前肾上腺皮质激素联合产后肺泡表面活性物质治疗新生儿呼吸窘迫综合征的临床疗效观察

目的观察产前肾上腺皮质激素联合产后肺泡表面活性物质治疗新生儿呼吸窘迫综合征的临床疗效。方法将本院收治的呼吸窘迫综合征患儿70例随机分为实验组与对照组,实验组37例患儿采用产前肾上腺皮质激素联合产后肺泡表面活性物质治疗,对照组33例患儿仅采用产后肺泡表面活性物质治疗。比较两组并发症发生率、死亡率、住院时间、机械通气时间以及呼吸机参数高浓度氧持续时间和最高MAP水平。结果实验组死亡率及并发症发生率都小于对照组（P〈0.05）;实验组住院时间和机械通气时间小于对照组（P〈0.05）;实验组呼吸机参数高浓度氧持续时间和最高MAP水平都小于对照组（P〈0.05）。结论产前肾上腺皮质激素联合产后肺泡表面活性物质治疗新生儿呼吸窘迫综合征临床疗效最显著,值得在临床推广应用。

Clinical efficacy observation of prenatal adrenal cortex hormone joint with postpartum pulmonary surfactant in treatment of neonatal respiratory distress syndrome

Objective To observe the clinical efficacy of prenatal adrenal cortex hormone joint with postpartum pulmonary surfactant in the treatment of neonatal respiratory distress syndrome. Methods Seventy cases of children with respiratory distress syndrome in our hospital were randomly divided into experimental group and control group, experimental group of 37 cases were treated with prenatal adrenal cortex hormone postpartum pulmonary surfactant treatment, and control group of 33 patients used onlypulmonary surfactant treatment. The two groups were compared the incidence of complications, mortality, hospital stay, duration of high concentrations of oxygen for the duration of mechanical ventilation and ventilator parameters, and the highest MAP level. Results The mortality and incidence of complications of experimental group was less than that of control group (P < 0.05); hospitalization time and mechanical ventilation time of experimental group was less than that of control group (P < 0.05); ventilator parameters of high concentrations of oxygen durationand and the highest MAP levels of experimental group were less than that of control group (P < 0.05). Conclusion The clinical efficacy of prenatal adrenal cortex hormone joint with postpartum pulmonary surfactant in treatment of neonatal respiratory distress syndrome is the most significant. It is worthy of clinical application.